USFDA concludes inspection at Zydus’ Ahmedabad facility

The cGMP inspection concluded with nil observations

Zydus Lifesciences has announced that the group’s injectables manufacturing facility at Zydus Biotech Park in Changodar, Ahmedabad, underwent USFDA inspection from 5th June to 13 June, 2023.

The cGMP inspection concluded with nil observations.

This signifies that the facility has met the standards set by the current Good Manufacturing Practices (GMP).

The GMP ensures that manufacturing processes and facilities are designed, monitored, and controlled effectively, guaranteeing the production of safe and effective products that meet quality standards.





biotech parkinspectionUSFDAZydus
Comments (0)
Add Comment